ACAD vs. ABBV

Last updated Apr 1, 2026

Compare and contrast key facts about ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV).

Performance

ACAD vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

ACAD vs. ABBV - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ACAD ACADIA Pharmaceuticals Inc.	-16.66%	45.56%	-41.39%	96.67%	-31.79%	-56.34%	24.96%	164.56%	-46.30%	4.40%
ABBV AbbVie Inc.	-4.05%	33.08%	18.86%	-0.23%	24.01%	32.43%	27.72%	1.47%	-0.96%	60.07%

Fundamentals

Market Cap ACAD : $3.81B ABBV : $385.83B
EPS ACAD : $2.30 ABBV : $2.38
PE Ratio ACAD : 9.69 ABBV : 91.23
PS Ratio ACAD : 3.54 ABBV : 6.30
Total Revenue (TTM) ACAD : $1.07B ABBV : $61.16B
Gross Profit (TTM) ACAD : $500.82M ABBV : $44.85B
EBITDA (TTM) ACAD : $122.49M ABBV : $28.29B

Returns By Period

In the year-to-date period, ACAD achieves a -16.66% return, which is significantly lower than ABBV's -4.05% return. Over the past 10 years, ACAD has underperformed ABBV with an annualized return of -2.50%, while ABBV has yielded a comparatively higher 19.07% annualized return.

ACAD

• 1D: 5.65%
• 1M: -9.36%
• YTD: -16.66%
• 6M: 4.31%
• 1Y: 34.02%
• 3Y*: 5.76%
• 5Y*: -2.75%
• 10Y*: -2.50%

ABBV

• 1D: 2.05%
• 1M: -6.29%
• YTD: -4.05%
• 6M: -4.63%
• 1Y: 7.29%
• 3Y*: 15.00%
• 5Y*: 19.40%
• 10Y*: 19.07%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ACAD vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD

ACAD Risk / Return Rank: 66
ACAD Sharpe Ratio Rank: 67
ACAD Sortino Ratio Rank: 68
ACAD Omega Ratio Rank: 63
ACAD Calmar Ratio Rank: 66
ACAD Martin Ratio Rank: 65

ABBV

ABBV Risk / Return Rank: 50
ABBV Sharpe Ratio Rank: 52
ABBV Sortino Ratio Rank: 44
ABBV Omega Ratio Rank: 44
ABBV Calmar Ratio Rank: 56
ABBV Martin Ratio Rank: 55

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ACAD	ABBV	Difference
Sharpe ratio Return per unit of total volatility	0.71	0.27	+0.44
Sortino ratio Return per unit of downside risk	1.51	0.54	+0.97
Omega ratio Gain probability vs. loss probability	1.17	1.07	+0.10
Calmar ratio Return relative to maximum drawdown	1.10	0.53	+0.58
Martin ratio Return relative to average drawdown	2.55	1.17	+1.38
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ACAD vs. ABBV - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is 0.71, which is higher than the ABBV Sharpe Ratio of 0.27. The chart below compares the historical Sharpe Ratios of ACAD and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ACAD	ABBV	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.71	0.27	+0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	0.86	-0.91
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.04	0.74	-0.78
Sharpe Ratio (All Time) Calculated using the full available price history	0.07	0.74	-0.67

Correlation

The correlation between ACAD and ABBV is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ACAD vs. ABBV - Dividend Comparison

ACAD has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.06%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ACAD ACADIA Pharmaceuticals Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ABBV AbbVie Inc.	3.06%	2.87%	3.49%	3.82%	3.49%	3.84%	4.41%	4.83%	3.89%	2.65%	3.64%	3.41%

Drawdowns

ACAD vs. ABBV - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for ACAD and ABBV.

Drawdown Indicators

	ACAD	ABBV	Difference
Max Drawdown Largest peak-to-trough decline	-96.29%	-45.09%	-51.20%
Max Drawdown (1Y) Largest decline over 1 year	-27.58%	-16.74%	-10.84%
Max Drawdown (5Y) Largest decline over 5 years	-57.87%	-21.92%	-35.95%
Max Drawdown (10Y) Largest decline over 10 years	-77.18%	-45.09%	-32.09%
Current Drawdown Current decline from peak	-60.95%	-9.64%	-51.31%
Average Drawdown Average peak-to-trough decline	-50.06%	-10.70%	-39.36%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.94%	8.12%	+3.82%

Volatility

ACAD vs. ABBV - Volatility Comparison

ACADIA Pharmaceuticals Inc. (ACAD) has a higher volatility of 13.50% compared to AbbVie Inc. (ABBV) at 7.57%. This indicates that ACAD's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ACAD	ABBV	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.50%	7.57%	+5.93%
Volatility (6M) Calculated over the trailing 6-month period	27.50%	19.03%	+8.47%
Volatility (1Y) Calculated over the trailing 1-year period	48.41%	27.12%	+21.29%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	56.19%	22.61%	+33.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.38%	25.71%	+36.67%

Financials

ACAD vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of -223.93M and revenue of 283.99M. Therefore, the gross margin over that period was -78.9%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ACADIA Pharmaceuticals Inc. reported an operating income of 17.39M and revenue of 283.99M, resulting in an operating margin of 6.1%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ACADIA Pharmaceuticals Inc. reported a net income of 273.57M and revenue of 283.99M, resulting in a net margin of 96.3%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.